New technologies are bringing into effect rapid change across the pharma industry, but no other aspect of the business is seeing innovation at the scale and speed of the clinical trial spac
Episode 45 of the pharmaphorum podcast heard from Dr Stuart Hill, how he’s seen the oncology landscape change and which of those he sees holding the most potential to improve patient outcom
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio